Role of cytokines in rheumatoid arthritis.

Analysis of cytokine mRNA and protein in rheumatoid arthritis tissue revealed that many proinflammatory cytokines such as TNF alpha, IL-1, IL-6, GM-CSF, and chemokines such as IL-8 are abundant in all patients regardless of therapy. This is compensated to some degree by the increased production of anti-inflammatory cytokines such as IL-10 and TGF beta and cytokine inhibitors such as IL-1ra and soluble TNF-R. However, this upregulation in homeostatic regulatory mechanisms is not sufficient as these are unable to neutralize all the TNF alpha and IL-1 produced. In rheumatoid joint cell cultures that spontaneously produce IL-1, TNF alpha was the major dominant regulator of IL-1. Subsequently, other proinflammatory cytokines were also inhibited if TNF alpha was neutralized, leading to the new concept that the proinflammatory cytokines were linked in a network with TNF alpha at its apex. This led to the hypothesis that TNF alpha was of major importance in rheumatoid arthritis and was a therapeutic target. This hypothesis has been successfully tested in animal models, of, for example, collagen-induced arthritis, and these studies have provided the rationale for clinical trials of anti-TNF alpha therapy in patients with long-standing rheumatoid arthritis. Several clinical trials using a chimeric anti-TNF alpha antibody have shown marked clinical benefit, verifying the hypothesis that TNF alpha is of major importance in rheumatoid arthritis. Retreatment studies have also shown benefit in repeated relapses, indicating that the disease remains TNF alpha dependent. Overall these studies demonstrate that analysis of cytokine expression and regulation may yield effective therapeutic targets in inflammatory disease.

[1]  Y. Lévy,et al.  Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. , 1994, The Journal of clinical investigation.

[2]  L. Davis,et al.  Elevated interleukin-10 levels in patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[3]  F. Pociot,et al.  An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles , 1993, The Journal of experimental medicine.

[4]  P. Hart,et al.  Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Banchereau,et al.  Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. , 2010, Arthritis and rheumatism.

[6]  D. Nelson,et al.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. , 1985, Journal of immunology.

[7]  I. Reid,et al.  Leukaemia inhibitory factor and bone cell function. , 1992, Ciba Foundation symposium.

[8]  M. Feldmann,et al.  Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. , 1992, Arthritis and rheumatism.

[9]  M. Burdick,et al.  Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. , 1992, The Journal of clinical investigation.

[10]  T. Vischer,et al.  Inhibitors of interleukin 1 activity in synovial fluids and in cultured synovial fluid mononuclear cells. , 1992, The Journal of rheumatology.

[11]  G. Kollias,et al.  The type I interleukin‐1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF‐transgenic mice , 1995, European journal of immunology.

[12]  H. D. Liggitt,et al.  Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  L. V. D. van de Putte,et al.  A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha , 1994, European journal of immunology.

[14]  P. Miossec,et al.  Rheumatoid Inflammatory T‐Cell Clones express mostly Th1 but also Th2 and Mixed (Th0‐Like) Cytokine Patterns , 1993, Scandinavian journal of immunology.

[15]  F. Wolfe,et al.  The mortality of rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[16]  T. Pincus,et al.  Active and latent forms of transforming growth factor beta activity in synovial effusions , 1989, The Journal of experimental medicine.

[17]  M. Burdick,et al.  Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. , 1994, The Journal of clinical investigation.

[18]  M. Feldmann,et al.  Beneficial effects of tumour necrosis factor‐alpha (TNF‐α) blockade in rheumatoid arthritis (RA) , 1995, Clinical and experimental immunology.

[19]  B Henderson,et al.  Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Feldmann,et al.  Detection of transforming growth factor‐beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures , 1990, Clinical and experimental immunology.

[21]  N. Olsen,et al.  Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue , 1994, The Journal of experimental medicine.

[22]  P. Miossec,et al.  Functional studies of soluble low-affinity interleukin-2 receptors in rheumatoid synovial fluid. , 1990, Arthritis and rheumatism.

[23]  G. Firestein,et al.  Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[24]  M. Feldmann,et al.  TNF Inhibitors are Produced Spontaneously by Rheumatoid and Osteoarthritic Synovial Joint Cell Cultures: Evidence of Feedback Control of TNF Action , 1995, Scandinavian journal of immunology.

[25]  H. Tabuchi,et al.  Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity. , 1991, The Journal of biological chemistry.

[26]  D. Wallach,et al.  A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. , 1989, The Journal of biological chemistry.

[27]  M. de Carli,et al.  Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. , 1993, Journal of immunology.

[28]  J. Case,et al.  Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints , 1990, The Journal of cell biology.

[29]  M. Turner,et al.  Expression of granulocyte‐macrophage colony‐stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor‐α , 1991, European journal of immunology.

[30]  B. Henderson,et al.  Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. , 1989, Clinical and experimental immunology.

[31]  A. Gearing,et al.  Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. , 1992, Biochemical and biophysical research communications.

[32]  P. Kapahi,et al.  Detection of a circulating form of vascular cell adhesion molecule‐1: raised levels in rheumatoid arthritis and systemic lupus erythematosus , 1993, Clinical and experimental immunology.

[33]  L. Joosten,et al.  Amelioration of established murine collagen‐induced arthritis with anti‐IL‐1 treatment , 1994, Clinical and experimental immunology.

[34]  J. Case,et al.  Production of platelet derived growth factor B chain (PDGF-B/c-sis) mRNA and immunoreactive PDGF B-like polypeptide by rheumatoid synovium: coexpression with heparin binding acidic fibroblast growth factor-1. , 1991, The Journal of rheumatology.

[35]  M. Feldmann,et al.  Transforming growth factor‐β1 in rheumatoid synovial membrane and cartilage pannus junction , 1991, Clinical and experimental immunology.

[36]  R. Russell,et al.  An interleukin 1 like factor stimulates bone resorption in vitro , 1983, Nature.

[37]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[38]  B. Beutler,et al.  Brief Definitive Report Cachectin/tumor Necrosis Factor Stimulates Collagenase and Prostaglandin E2 Production by Human Synovial Cells and Dermal , 2022 .

[39]  G. Firestein,et al.  Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis , 1988, The Journal of experimental medicine.

[40]  G. Firestein,et al.  Alpha 4/beta 1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. , 1992, Journal of immunology.

[41]  J. Saklatvala,et al.  Pig interleukin 1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever , 1985, The Journal of experimental medicine.

[42]  W. B. Berg,et al.  Flare‐up of experimental arthritis in mice with murine recombinant IL‐1 , 1992, Clinical and experimental immunology.

[43]  E. Brahn,et al.  Angiogenesis inhibition suppresses collagen arthritis , 1992, The Journal of experimental medicine.

[44]  N. Sarvetnick,et al.  Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma , 1988, Cell.

[45]  A. Bendele,et al.  In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice. , 1988, Journal of immunology.

[46]  J. Banchereau,et al.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Feldmann,et al.  Two inhibitors of pro‐inflammatory cytokine release, interleukin‐10 and interleukin‐4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes , 1994, European journal of immunology.

[48]  J. Vaughan,et al.  Altered lymphocyte reactivity in rheumatoid arthritis. , 1976, Arthritis and rheumatism.

[49]  G. Nuki,et al.  Tumour necrosis factor in synovial exudates. , 1988, Annals of the rheumatic diseases.

[50]  M. Palladino,et al.  Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[51]  G. Buirski,et al.  Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides. , 1993, Arthritis and rheumatism.

[52]  C. Figdor,et al.  Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. , 1990, Blood.

[53]  S. Breit,et al.  Identification of the major fibroblast growth factors released spontaneously in inflammatory arthritis as platelet derived growth factor and tumour necrosis factor‐alpha , 1991, Clinical and experimental immunology.

[54]  G. Mundy,et al.  Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. , 1987, Journal of immunology.

[55]  J. Banchereau,et al.  Interleukin‐4 but not interleukin‐10 inhibits the production of leukemia inhibitory factor by rheumatoid synovium and synoviocytes , 1994, European journal of immunology.

[56]  S. Wahl,et al.  Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. , 1991, The Journal of clinical investigation.

[57]  R. Terkeltaub,et al.  Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. , 1992, Journal of immunology.

[58]  J. Dayer,et al.  Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. , 1993, European cytokine network.

[59]  G. Tosato,et al.  IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. , 1993, International immunology.

[60]  J. Banchereau,et al.  Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis. , 1992, Arthritis and rheumatism.

[61]  G. Haines,et al.  Adhesion molecule expression in human synovial tissue. , 1993, Arthritis and rheumatism.

[62]  B. Scallon,et al.  Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. , 1993, Molecular immunology.

[63]  A. Meager,et al.  Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. , 1988, Clinical and experimental immunology.

[64]  M. Burdick,et al.  Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. , 1994, The Journal of clinical investigation.

[65]  E. Remmers,et al.  Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. , 1993, The Journal of clinical investigation.

[66]  L. Punzi,et al.  Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. , 1993, Arthritis and rheumatism.

[67]  S. Wahl,et al.  Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta , 1990, The Journal of experimental medicine.

[68]  D. Wendling,et al.  Interleukin-6 antibodies in rheumatoid arthritis. , 1994, Journal of interferon research.

[69]  W. B. Berg Uncoupling of inflammation and joint destruction in arthritis: Pivotal role of IL-1 in destruction , 1995 .

[70]  A. Cope,et al.  Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells. , 1993, Cytokine.

[71]  P. Young,et al.  Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[72]  E. Nilsson,et al.  Isolation and characterization of a tumor necrosis factor binding protein from urine , 1989, European journal of haematology.

[73]  M. Sporn,et al.  Transforming growth factor-beta production by synovial tissues from rheumatoid patients and streptococcal cell wall arthritic rats. Studies on secretion by synovial fibroblast-like cells and immunohistologic localization. , 1989, Journal of immunology.

[74]  M. Feldmann,et al.  Immunoregulatory role of interleukin 10 in rheumatoid arthritis , 1994, The Journal of experimental medicine.

[75]  W. Cooper,et al.  Acceleration of onset of collagen‐induced arthritis by intra‐articular injection of tumour necrosis factor or transforming growth factor‐beta , 1992, Clinical and experimental immunology.

[76]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[77]  N. Voelkel,et al.  Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. , 1995, The Journal of clinical investigation.

[78]  P. Colville-Nash,et al.  Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. , 1992, Annals of the rheumatic diseases.

[79]  M. Feldmann,et al.  Cytokine production in culture by cells isolated from the synovial membrane. , 1989, Journal of autoimmunity.

[80]  G. Firestein,et al.  IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. , 1992, Journal of immunology.

[81]  R. Jonsson,et al.  Treatment with gamma-interferon triggers the onset of collagen arthritis in mice. , 1988, Arthritis and rheumatism.

[82]  M. Burdick,et al.  Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. , 1995, The Journal of clinical investigation.

[83]  D. Weiner,et al.  Regulation of synovial cell growth. Coexpression of transforming growth factor beta and basic fibroblast growth factor by cultured synovial cells. , 1992, Arthritis and rheumatism.

[84]  J. Dayer,et al.  Contact-dependent stimulation of monocytic cells and neutrophils by stimulated human T-cell clones. , 1995, Immunology.

[85]  M. Sporn,et al.  Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation , 1989, The Journal of experimental medicine.

[86]  C. Dinarello,et al.  Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies. , 1986, The Journal of clinical investigation.

[87]  J. Ghrayeb,et al.  Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. , 1995, Immunology.

[88]  S. Wahl,et al.  Reversal of acute and chronic synovial inflammation by anti- transforming growth factor beta , 1993, The Journal of experimental medicine.

[89]  S. McColl,et al.  Production of monocyte chemotactic protein–1 in human type B synoviocytes. synergistic effect of tumor necrosis factor α and interferon-γ , 1993 .

[90]  P. Emery,et al.  Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis. , 1984, Clinical and experimental immunology.

[91]  A. Gearing,et al.  Circulating adhesion molecules in disease. , 1993, Immunology today.

[92]  D. Morton,et al.  IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. , 1989, Journal of immunology.

[93]  L. Klareskog,et al.  Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[94]  J. Alcocer-Varela,et al.  In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. , 1994, Arthritis and rheumatism.

[95]  M. Turner,et al.  Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells , 1990, European journal of immunology.

[96]  R. Gentz,et al.  Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. , 1992, Immunology.

[97]  D. Heinegård,et al.  Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. , 1988, Arthritis and rheumatism.

[98]  M. Feldmann,et al.  Human T-cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells. , 1985, Science.

[99]  F. Podlaski,et al.  Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[100]  G. Kingsley,et al.  The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. , 1995, British journal of rheumatology.

[101]  M. Jayson,et al.  Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1. , 1988, Clinical and experimental immunology.

[102]  J. Neefjes,et al.  E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. , 1992, Immunology.

[103]  R. Jubb,et al.  The effect of synovial tissue on the breakdown of articular cartilage in organ culture. , 1977, Arthritis and rheumatism.

[104]  G. Firestein,et al.  Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. , 1991, Journal of immunology.

[105]  D. Wendling,et al.  Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. , 1993, The Journal of rheumatology.

[106]  M. Feldmann,et al.  Cytokine production in the rheumatoid joint: implications for treatment. , 1990, Annals of the rheumatic diseases.

[107]  J. Symons,et al.  In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis. , 1992, Clinical immunology and immunopathology.

[108]  K. Matsushima,et al.  Localisation of interleukin 8 in the synovial membrane, cartilage-pannus junction and chondrocytes in rheumatoid arthritis. , 1994, Scandinavian journal of rheumatology.

[109]  A. Cope,et al.  Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints , 1992, European journal of immunology.

[110]  B. Hazleman,et al.  Transforming growth factor beta stimulates the production of the tissue inhibitor of metalloproteinases (TIMP) by human synovial and skin fibroblasts. , 1991, Biochimica et biophysica acta.

[111]  B. Beutler,et al.  The biology of cachectin/TNF--a primary mediator of the host response. , 1989, Annual review of immunology.

[112]  T. Taniguchi,et al.  Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. , 1988, Clinical and experimental immunology.

[113]  S. McColl,et al.  Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. , 1993, The Journal of biological chemistry.

[114]  R. Strieter,et al.  Interleukin-8 as a macrophage-derived mediator of angiogenesis. , 1992, Science.

[115]  A. Silman,et al.  Twin concordance rates for rheumatoid arthritis: results from a nationwide study. , 1993, British journal of rheumatology.

[116]  T. Hirano,et al.  Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis , 1988, European journal of immunology.

[117]  M. Feldmann,et al.  Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. , 1992, British journal of rheumatology.

[118]  R. Fernandez-Botran Soluble cytokine receptors: their role in immunoregulation , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[119]  G. Ciliberto,et al.  Interleukin‐6 deficient mice are protected from bone loss caused by estrogen depletion. , 1994, The EMBO journal.

[120]  D. Glass,et al.  Very late activation antigens on rheumatoid synovial fluid T lymphocytes. Association with stages of T cell activation. , 1986, The Journal of clinical investigation.

[121]  M. Feldmann,et al.  INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS , 1989, The Lancet.

[122]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[123]  K. Tracey,et al.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia , 1989, The Journal of experimental medicine.

[124]  J. Ghrayeb,et al.  Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. , 1993, Arthritis and rheumatism.

[125]  P. Gregersen,et al.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. , 1987, Arthritis and rheumatism.

[126]  G. Trinchieri,et al.  Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells , 1993, The Journal of experimental medicine.

[127]  E. Brahn,et al.  Effects of tumor necrosis factor alpha (TNF-alpha) on collagen arthritis. , 1992, Lymphokine and cytokine research.

[128]  M. Feldmann,et al.  Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. , 1992, British journal of rheumatology.

[129]  M. Feldmann,et al.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[130]  P. Wooley,et al.  Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. , 1993, Journal of immunology.

[131]  A. Simon,et al.  Divergent T-cell cytokine patterns in inflammatory arthritis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[132]  C. Dinarello,et al.  Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. , 1986, The Journal of clinical investigation.

[133]  M. Feldmann,et al.  ROLE OF ABERRANT HLA-DR EXPRESSION AND ANTIGEN PRESENTATION IN INDUCTION OF ENDOCRINE AUTOIMMUNITY , 1983, The Lancet.

[134]  D. Taub,et al.  Review of the chemokine meeting the Third International Symposium of Chemotactic Cytokines. , 1993, Cytokine.

[135]  B. Dewald,et al.  Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis. , 1991, The Journal of clinical investigation.

[136]  J. Winer,et al.  The vascular endothelial growth factor family of polypeptides , 1991, Journal of cellular biochemistry.

[137]  M. Sporn,et al.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth , 1986, The Journal of experimental medicine.

[138]  R. Bucala,et al.  Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts , 1991, The Journal of experimental medicine.

[139]  B. Beutler,et al.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1 , 1986, The Journal of experimental medicine.

[140]  G. Trinchieri Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. , 1995, Annual review of immunology.

[141]  E. Brahn,et al.  Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. , 1994, Cellular immunology.

[142]  A. Steere,et al.  Balance of synovial fluid IL-1β and IL-1 receptor antagonist and recovery from Lyme arthritis , 1993, The Lancet.

[143]  W. Arend,et al.  Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils. , 1993, Arthritis and rheumatism.

[144]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[145]  F. Nicoletti,et al.  Biphasic effect of interferon‐γ in murine collagen‐induced arthritis , 1995, European journal of immunology.

[146]  C. Brinckerhoff,et al.  Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? , 1994, Arthritis and rheumatism.

[147]  R. Płoski,et al.  A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1α polymorphism , 1995 .

[148]  H. Kondo,et al.  Expression of the chemokine superfamily in rheumatoid arthritis , 1994, Clinical and experimental immunology.

[149]  J. Dayer,et al.  Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. , 1992, The Journal of clinical investigation.

[150]  R. Strieter,et al.  Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. , 1992, Clinical immunology and immunopathology.

[151]  G. Kersley Report on an Enquiry into the Aetiological Factors associated with Rheumatoid Arthritis , 1953 .

[152]  G. Mundy,et al.  Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. , 1986, Journal of immunology.

[153]  P. Villiger,et al.  Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis. , 1992, The Journal of clinical investigation.

[154]  G. Haines,et al.  Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. , 1994, Journal of immunology.

[155]  J. Hamilton,et al.  Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs , 1993, The Lancet.

[156]  M. Howard,et al.  Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice , 1994, The Journal of experimental medicine.

[157]  J. Lunec,et al.  HYPOXIC-REPERFUSION INJURY IN THE INFLAMED HUMAN JOINT , 1989, The Lancet.

[158]  J. Woody,et al.  Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis , 1994, The Lancet.

[159]  C. Jacob,et al.  Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis , 1988, Nature.

[160]  N. Sarvetnick,et al.  Loss of pancreatic islet tolerance induced by β-cell expression of interferon-γ , 1990, Nature.

[161]  D. Wallach,et al.  Soluble cytokine receptors are present in normal human urine , 1989, The Journal of experimental medicine.

[162]  G. Janossy,et al.  RHEUMATOID ARTHRITIS: A DISEASE OF T-LYMPHOCYTE/MACROPHAGE IMMUNOREGULATION , 1981, The Lancet.

[163]  N. Olsen,et al.  Transforming growth factor beta 1 (TGF-beta 1) induced neutrophil recruitment to synovial tissues: implications for TGF-beta-driven synovial inflammation and hyperplasia , 1991, The Journal of experimental medicine.

[164]  M. Feldmann,et al.  Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[165]  M. Field,et al.  Expression of GM-CSF receptor In rheumatold arthritis , 1993, The Lancet.

[166]  R. Strieter,et al.  Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. , 1991, Journal of immunology.

[167]  P. Wooley,et al.  The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. , 1993, Arthritis and rheumatism.

[168]  A. Cope,et al.  Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. , 1992, Arthritis and rheumatism.

[169]  J. Banchereau,et al.  Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. , 1995, Journal of immunology.

[170]  G. Firestein,et al.  How important are T cells in chronic rheumatoid synovitis? , 1990, Arthritis and rheumatism.

[171]  A. Ferrante,et al.  Granulocyte-macrophage colony-stimulating factor augments neutrophil-mediated cartilage degradation and neutrophil adherence. , 2010, Arthritis and rheumatism.

[172]  M. Feldmann,et al.  TNF alpha--a pivotal role in rheumatoid arthritis? , 1992, British journal of rheumatology.

[173]  H. Paulus,et al.  Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. , 1990, Arthritis and rheumatism.

[174]  R. Maini,et al.  Increased limb involvement in murine collagen‐induced arthritis following treatment with anti‐interferon‐gamma , 1993, Clinical and experimental immunology.

[175]  T. Hirano,et al.  Molecular cloning and expression of an IL-6 signal transducer, gp130 , 1990, Cell.

[176]  J. Symons,et al.  Purification and characterization of a novel soluble receptor for interleukin 1 , 1991, The Journal of experimental medicine.

[177]  M. Turner,et al.  Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. , 1988, Clinical and experimental immunology.

[178]  J. Dayer,et al.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. , 1990, Arthritis and rheumatism.

[179]  A. D. de Vos,et al.  Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. , 1991, Journal of immunological methods.

[180]  A. Cerami,et al.  Identification and characterization of macrophage inflammatory protein 2. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[181]  F. Houssiau,et al.  Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. , 1988, Arthritis and rheumatism.

[182]  G. Firestein,et al.  Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. , 1989, The Journal of clinical investigation.

[183]  D. Novick,et al.  Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody. , 1992, Cytokine.

[184]  M. Lotz,et al.  Transforming growth factor-beta and cellular immune responses in synovial fluids. , 1990, Journal of immunology.

[185]  F. Breedveld,et al.  T Cells Cloned from Human Rheumatoid Synovial Membrane Functionally Represent the Th 1 Subset , 1992, Scandinavian Journal of Immunology.

[186]  T. Mosmann,et al.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones , 1989, The Journal of experimental medicine.

[187]  A. Cope,et al.  Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. , 1994, The Journal of clinical investigation.

[188]  M. Sporn,et al.  Cytokines and growth regulation of synoviocytes from patients with rheumatoid arthritis and rats with streptococcal cell wall arthritis. , 1990, Growth factors.

[189]  N. Beck,et al.  Depression in rheumatoid arthritis. , 1988, The Journal of rheumatology.

[190]  K. Matsushima,et al.  Expression of monocyte chemotactic and activating factor in rheumatoid arthritis. Regulation of its production in synovial cells by interleukin-1 and tumor necrosis factor. , 1993, Arthritis and rheumatism.

[191]  L M Wakefield,et al.  Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[192]  C. Dinarello,et al.  The interleuldn-1 family: 10 years of discovery’ , 2004 .

[193]  R. Puri,et al.  Human Cytokines: Their Role in Disease and Therapy , 1995 .

[194]  G. Roodman Perspectives: Interleukin‐6: An osteotropic factor? , 1992 .

[195]  J. Lamb,et al.  Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells , 1984, Nature.

[196]  P. Lipsky,et al.  Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[197]  M. Feldmann,et al.  Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. , 1991, Arthritis and rheumatism.

[198]  R. Maki,et al.  Quantitative analysis of cytokine gene expression in rheumatoid arthritis. , 1990, Journal of immunology.

[199]  M. Feldmann,et al.  High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. , 1995, Arthritis and rheumatism.

[200]  S. Wahl,et al.  Transforming growth factor beta: the good, the bad, and the ugly , 1994, The Journal of experimental medicine.

[201]  J. Dayer,et al.  A human inhibitor of tumor necrosis factor alpha , 1988, The Journal of experimental medicine.

[202]  D. Goddard,et al.  Autocrine regulation of rheumatoid arthritis synovial cell growth in vitro. , 1990, Cytokine.